Newron 1999

About Newron Pharmaceuticals

Newron Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing new treatments for patients with diseases of the central and peripheral nervous system. Its key achievement is the development and approval of Xadago® (safinamide), a once-daily oral add-on therapy for Parkinson's disease patients experiencing motor fluctuations. The company's strategy focuses on leveraging its expertise in neurology to advance a pipeline of novel compounds for rare and underserved neurological conditions, including Rett syndrome and other rare epilepsies.

Therapeutic Areas

Other Rare Epilepsy Drugs